Hanmi Pharm Signs Agreement to Transfer Ophthalmic New Drug Sales Rights in China with Chinese Pharmaceutical Company
[Asia Economy Reporter Ji Yeon-jin] Hanmi Pharmaceutical announced on the 3rd that it has signed a contract to transfer the exclusive development and sales rights in China for the ophthalmic new drug 'Luminate' (active ingredient: Risuteganib), which it licensed from the US company Allegro, to the Chinese pharmaceutical company Apamed Therapeutics.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- Blue House Protests Bloomberg's "Distorted Reporting on AI National Dividend"
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
